Please login to the form below

Not currently logged in
Email:
Password:

SillaJen

This page shows the latest SillaJen news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

French biotech Transgene has abandoned a phase 3 trial of its SillaJen-partnered liver cancer therapy after an interim analysis suggested almost no chance of a positive outcome. ... Transgene said in a statement that South Korean biotech SillaJen had

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics